South Rampart Pharma
2:15 PM - 2:30 PM (EST), Monday, February 6, 2023 ・ Winter Garden
Through South Rampart Pharma, we are developing SRP-001, a novel, next-gen analgesic molecule for treating acute pain (granted NCE IP). We are working to advance the safer treatment of pain away from opioids (abuse potential) and risks with overuse of acetaminophen/Tylenol (liver toxic risk) and NSAIDs (kidney and GI toxicity). We are advancing quickly in our ongoing Phase 1 clinical trial [ClinicalTrials.gov Identifier: NCT05484414] and, thus, actively readying for our forthcoming Phase 2 trial in an acute pain model.
SRP-001 exhibits: 1) Clinically validated MOA, same as acetaminophen by way of AM404 production; 2) Significantly improved safety profile, No liver toxicity as SRP-001 does not produce NAPQI and preserves tight junctions; 3) Ongoing Phase 1 trial has dosed >40 healthy volunteers so far with no observed safety concerns; 4) Standout in-vivo efficacy in validated animal models consistent pain relief; and 5) NIH funding: Secured prestigious NIH/NINDS ‘fast-track’ STTR.
SRP-001 exhibits: 1) Clinically validated MOA, same as acetaminophen by way of AM404 production; 2) Significantly improved safety profile, No liver toxicity as SRP-001 does not produce NAPQI and preserves tight junctions; 3) Ongoing Phase 1 trial has dosed >40 healthy volunteers so far with no observed safety concerns; 4) Standout in-vivo efficacy in validated animal models consistent pain relief; and 5) NIH funding: Secured prestigious NIH/NINDS ‘fast-track’ STTR.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Louisiana
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
SRP-001
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
